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Abstract
Background: Probiotics are effective in inflammatory bowel diseases. Clinical effectiveness and dose dependency of E. 
coli Nissle (EcN) enemas were investigated in ulcerative colitis (UC).
Methods: In a double-blind study, 90 patients with moderate distal activity in UC were randomly assigned to 
treatment with either 40, 20, or 10 ml enemas (N = 24, 23, 23) containing 10E8 EcN/ml or placebo (N = 20). The study 
medication was taken once daily for at least 2 weeks. After 2, 4 and/or 8 weeks the clinical DAI was assessed together 
with tolerance to treatment. Patients who reached clinical DAI ≤ 2 within that time were regarded as responders.
Results: According to ITT analysis the number of responders was not significantly higher in the EcN group than in the 
placebo group (p = 0.4430, 2-sided). However, the Jonckheere-Terpstra rank correlation for dose-dependent efficacy 
indicated a significant correlation of per-protocol responder rates (p = 0.0446, 2-sided). Time to remission was shortest 
with EcN 40 ml, followed by EcN 20 ml. The number of adverse events did not differ notably.
Conclusion: In contrast to ITT analysis, efficacy of rectal EcN application was significant in PP and points to EcN as a 
well tolerated treatment alternative in moderate distal UC.
Trial registration: German Clinical Trials Register DRK00000234.
Background
Ulcerative colitis (UC) is an inflammatory bowel disease
characterised by acute inflammation of the colonic
mucosa and intermittent, symptom-free periods of
remission [1]. Its aetiology is currently not well under-
stood, but a number of hypotheses including genetic fac-
tors, alimentation, autoimmunogenicity, and an
imbalanced gut microflora have been put forward [2,3].
Moreover, a number of different disease activity indices
have been suggested for use in clinical trials [4]. Although
spontaneous remissions have been observed, the disease
usually requires treatment. The number of treatment
o p t i o n s  f o r  d i s t a l  U C  h a v e  i n c r e a s e d  i n  r e c e n t  y e a r s ,
essentially by two different approaches: containment of
the immune response and modulation of the intestinal
microflora [1]. Examples of the former include topical
compounds like 5-aminosalicylic acid (mesalazine), ste-
roids, cytoprotective agents, lidocaine, short-chain fatty
acids, cyclosporine [1], and enemas [ 5]. However , pr o-
longed use of chemicals such as corticosteroids may
result in serious complications, hence a number of treat-
ment alternatives and various routes of administration
are being investigated [6].
Modulation of the intestinal microflora is based on
Alfred Nissle's observation [7] that the application of
Escherichia coli Nissle 1917 (EcN) can have a positive
effect on UC. His probiotic hypothesis led to a number of
studies. Successful oral application of microorganisms in
UC remission induction or maintenance, such as EcN [8],
S. boulardii [9], bifidobacteria [10], and others [11,12] as
well as the role of probiotic functional foods or probiotic
therapies in inflammatory bowel disease was reviewed by
[13-16]. Furthermore, the effect of probiotics on acute
disease was investigated [17], with EcN currently appear-
ing to be one of the most promising candidates. The
rational of probiotic treatment was recently further sup-
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ported by findings of reduced diversity in the dominant
faecal microbiota of UC patients [18]. In addition, good
tolerance of rectally applied EcN was already been shown
in a phase-I study involving 80 patients (data on file at
Ardeypharm). In the present trial we investigated the
treatment of patients suffering from active UC proctitis/
proctosigmoiditis, with 40, 20, or 10 ml EcN enemas (108
EcN/ml) for 4 to 8 weeks and compared it to placebo.
Methods
This was an explorative, randomised, double-blind, pla-
cebo-controlled, parallel-group, multicentre, phase-II
dose-finding study. It was performed in accordance with
the requirements of GCP and the Revised Declaration of
Helsinki, approved by the independent ethics committee
of the Medical Association Westphalia-Lippe, Muenster,
Germany, and registered with the German national regu-
latory authority (Federal Institute for Drugs and Medical
Devices submission number No. 4015691).
Patients
Eligible participants were recruited in 10 centres (1 uni-
versity hospital, 4 community hospitals, and 5 commu-
nity based gastroenterologists) in Germany between Nov
1999 and June 2002. All were treated as out-patients.
Prior to admission to the trial, each patient was informed
by the investigator about the nature, significance, and
possible consequences of the trial and its procedure as
well as efficacy and adverse drug effects of the trial medi-
cation.
All patients gave their express informed consent in
written form.
Due to its explorative character, sample size calculation
was not possible in this trial. The objective was hypothe-
sis generation. However, the general design of ran-
domised, explorative, phase-II dose-finding studies was
taken into consideration. A total of 90 patients between
18 and 70 years of age were admitted to the study, who
had a confirmed diagnosis of acute UC proctitis/procto-
sigmoiditis with mild to moderate disease activity. Active
disease was defined as a Disease Activity Index (DAI)
according to Sutherland of 4-9 [19]. Proctitis with inflam-
mation beginning at the anus up to ≤ 15 cm, and procto-
sigmoiditis with inflammation beginning at the anus up
to the end of colon sigmoideum (about 25 - 30 cm from
anus) were acceptable for inclusion, if verified by endos-
copy and histology. Inclusion criteria further stipulated at
least two confirmed prior manifestations of disease.
Exclusion criteria were other causes of acute proctitis
or proctosigmoiditis such as infections, medical drugs,
radiation, ischaemia of affected intestinal segments, and
Crohn's disease. A history of stool incontinence, perianal
fistulae, major colonic surgery, colorectal carcinoma, or
stenoses too, led to exclusion just as other severe accom-
panying diseases. Participation in another clinical trial
either simultaneously or within 30 days prior to enrol-
ment was forbidden by protocol. Also not permissible
was medication such as oral EcN within 4 weeks prior to
the study, rectal treatment with steroids or aminosalicy-
lates within 2 weeks before the study, immunosuppres-
sants within 90 days before inclusion, and antibiotics or
sulphonamides during the study course. Finally, a lack of
cooperation, inadequate contraception, pregnancy or
breast feeding, drug or alcohol dependency, neurotic per-
sonality, and obesity were reasons for exclusion. Permissi-
ble concomitant therapies included loperamide drops to
improve retention capacity for enemas, and oral UC
maintenance treatment with aminosalicylates or steroids
at a constant level for at least two weeks prior to the
s t u d y .  H o w e v e r ,  a n y  d o s a g e  a l t e r a t i o n  l e d  t o  e x c l u s i o n
from per-protocol analysis. The decision to exclude a
patient was taken by an independent steering committee
before unblinding of the random code. It was not consid-
ered necessary to actively verify the effectiveness of
blinding.
Study medication
The investigational drug was an enema containing probi-
otic, non-pathogenic Escherichia coli strain Nissle 1917
(manufactured by Ardeypharm, Herdecke, Germany; 108
viable microorganisms per ml). Other components were
purified water, sodium chloride, potassium chloride,
magnesium sulfate, magnesium chloride. As placebo an
identical enema preparation devoid of the active sub-
stance, was used.
Patients were randomly assigned to one of three EcN
groups EcN 40 ml, EcN 20 ml, EcN 10 ml or placebo. The
placebo group was pooled from three groups that
matched the three different enema volumes used in the
EcN groups (6 patients received 10-ml enemas, 7 received
20-ml enemas, and 7 received 40-ml enemas). Therefore,
blinding was granted with regard to the use of the active
substance or placebo.
Enemas were stored in the fridge and ready to use after
30 minutes at room temperature. I.r application was car-
ried out in the evening and maintained once daily for at
least 2 weeks. Viability of the study medication was veri-
fied regularly.
Study design
Eligible patients were enrolled and randomised to treat-
ment with either 40, 20, or 10 ml EcN (24, 23, and 23
patients, respectively) or placebo (20 patients; Figure 1).
Using standard predetermined randomisation tables and
the order of enrolment, patients received a randomisation
number. No patient was randomised in order to replace a
patient who left the study prematurely. Blinding of the
investigator and patient was ensured by the provision ofMatthes et al. BMC Complementary and Alternative Medicine 2010, 10:13
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study medication identical in appearance, with a patient
specific randomisation number.
Patients applied the enemas in the evening before going
to sleep and retained it in the rectum for as long as possi-
ble. As per protocol, patients left the study after 2, 4, or 8
weeks. If after 2 weeks of treatment health condition had
not improved, patients were classified as non-responders
and discontinued. This early discontinuation was necessi-
tated by ethical considerations on the use of placebo,
even though one can assume that continued treatment
would have resulted in higher responder rates. If remis-
sion was achieved after 4 or 8 weeks of treatment,
patients finished the study and were classified as
responders. The flow of patients is shown in Figure 1.
Clinical DAI was defined comprising the parameters
"stool frequency", "rectal bleeding" and "assessment of
disease activity by physician"; sigmoidoscopies were per-
formed with the initial and final examination. Patients
had to keep a diary for daily self-assessments of global
health on a 100-mm visual-analogue scale (VAS). An
additional scale used for global assessment of health by
patients and investigators comprised six categories, i.e.
complete recovery, noticeable, moderate or slight
improvement, no changes, and deterioration [20]. At con-
trol visits (week 2, 4, and 8) these data were combined
with additional parameters assessed (e.g. efficacy of the
study medication as assessed by patients and investiga-
tors, and practicability of treatment as assessed by
patients) and transferred to a case report form. Efficacy
and practicability of treatment were determined on 5-
point scales ("very good", "good", "moderate", "barely sat-
isfactory", "poor"). Empty medication containers were
Figure 1 Patient flow chart.Matthes et al. BMC Complementary and Alternative Medicine 2010, 10:13
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returned to the centres in order to check for patient com-
pliance. At the control visits, safety parameters were also
monitored and recorded by the investigators together
with all adverse events (AEs).
Evaluation
The objective of this evaluation was to further character-
ize the involvement of the gut microflora in ulcerative
colitis, hence to test the probiotic hypothesis. The pri-
mary outcome measured was the number of patients who
reached clinical remission within the study period under
EcN therapy versus placebo. Clinical remission was
defined as a clinical DAI ≤ 2, which even meets a more
recent and stringent classification of patient defined end-
points [21]. Patients with thus defined clinical remission
at the last documented control examination (last obser-
vation carried forward (LOCF)) were regarded as
responders.
Secondary outcome criteria were the time to remission,
endoscopic mucosal healing (DAI = 0), and disappear-
ance of histological signs of significant inflammation
(according to [22]). In addition, safety monitoring of vital
parameters and standard laboratory values were per-
formed. For the assessments of AEs and general tolerance
to treatment by the patients and investigators, a 5-point
scale again was used (please cf. above).
Statistical analysis
The one-sided Jonckheere-Terpstra test was used for
explorative investigation whether a dose-effect relation
existed between the 4 regimens of treatment. The zero
hypothesis, equal efficacy of the 4 treatment regimens
was tested against the alternative of treatment rankings.
This assumes a difference between EcN and placebo and
differences amongst the 3 EcN groups with increasing
efficacy achieved by larger volumes of EcN. The statistical
evaluation for the comparison of the treatments was car-
ried out on the primary target parameter, the remission
rate defined as the percentage of patients with clinical
DAI ≤ 2.
Fisher's exact test was used to evaluate adverse events.
Data on secondary objectives were compared descrip-
tively. Two sets of patients were analysed: An intent-to-
treat population (ITT), including all patients who con-
firmedly took at least one dose of the study medication,
and a per-protocol population (PP). Both the ITT and PP
evaluations were carried out for all efficacy parameters.
Safety and tolerance was analysed using ITT data only.
All biostatistical evaluations were performed by ClinRe-
search GmbH, Cologne, Germany, using the statistical
software package SAS®, version 8.2.
Results
Patient Characteristics
Of 90 patients enrolled in the study, 88 received at least
one dose of study medication and provided at least one
post-baseline value; hence they were included in the ITT
analysis set (Figure 1). 55.7% were male and 44.3% female,
all between the age of 21 and 67 years, and a BMI
between 16.3 and 46.7 kg/m2. There were no apparent
differences between the study groups at baseline. Simi-
larly, their case histories were comparable (data not
shown). The majority of patients had concomitant medi-
cal treatment of their acute UC proctitis/proctosigmoidi-
tis at baseline (Table 1). Mesalazine was the most
common antiinflammatory drug while acetylsalicylic acid
and paracetamol were primarily used as analgesics. Over-
all, neither the concomitant diseases nor concomitant
therapies varied significantly between the study groups.
Abnormalities of colon-descendens histology were
observed in 20/88 patients at baseline. These split how-
ever evenly between the groups. Before unblinding a
steering committee assessed protocol violations in 45/88
patients (51.1%) of the ITT data set (12/23 [52.2%], 9/23
[39.1%], 12/22 [54.5%] in the 40, 20, and 10 ml EcN
groups, respectively, as well as 12/20 (60.0%) in the pla-
cebo group). Major protocol deviations comprised viola-
tions of inclusion criteria, intake of non-permissible
concomitant medication for more than 3 days, intake of ≥
3 g mesalazine or sulfasalazine during the entire study,
discontinuation of ≥ 3 g mesalazine immediately before
the start of study, intake or application of steroids (≥ 3 mg
local or > 10 mg systemic) during the study, and intake of
of less than 70% of study medication. Accordingly, the PP
analysis set comprised 57 patients (17/23, 18/23, and 11/
22 EcN 40, 20, and 10 ml patients, respectively, and 11/20
placebo-treated patients). Premature discontinuation of
the study for lack of efficacy occurred in 35/88 patients
(7/23, 8/23, and 10/22 in the 40, 20, and 10 ml EcN
groups, respectively, and 10/20 in the placebo group).
The number of patients in the study at the scheduled vis-
its is shown in Figure 1.
Primary objective
Remission rates in 57/90 PP patients were clearly dose-
dependent (Figure 2): EcN 40 ml (9/17 [52.9%]), 20 ml (8/
18 [44.4%]), 10 ml (3/11 [27.3%]), and placebo (2/11
[18.2%]). As would be expected, this dose-dependency
was less pronounced in the ITT analysis (10/23 [43.5%],
11/23 [47.8%], 8/22 [36.4%], and 7/20 [35.0%] in the EcN
40 ml, 20 ml 10 ml, and placebo group, respectively). Jon-
ckheere-Terpstra rank-correlation test for dose-depen-
dent efficacy indicated statistical significance (p = 0.0446
two sided) for PP but not ITT analysis (p = 0.4430 two
sided).
Secondary objectives
Time to remission was shorter in the 40 ml and 20 ml
EcN groups than in the 10 ml EcN and placebo groups
(Figure 2). With regard to endoscopy, results were also
f a v o u r a b l e  f o r  E c N .  O f  a l l  P P  p a t i e n t s  w i t h  a b n o r m a l
mucosal findings at baseline (N = 57), 8/17 (47.6%, 40 mlMatthes et al. BMC Complementary and Alternative Medicine 2010, 10:13
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EcN), 7/18 (38.9%, 20 ml EcN), 5/11 (45.5%, 10 ml EcN),
and 3/11 (27.3%, placebo) showed remission or improve-
ment of the histological score. Similar results were
obtained in the ITT population. Vulnerability of the
intestinal mucosa and abnormal histological findings in
the rectum generally decreased from admission to the
last control examination as shown in Figure 3. However,
as histology revealed, mucosal healing was most promi-
nent in the EcN 40 ml group. At baseline only 2 PP
patients allocated to EcN 40 ml presented remission
while 10 patients showed moderate or high-grade disease
activity as identified histologically. At the final visit after 8
weeks the number of PP patients in remission had
increased to 8, 2 PP patients still showed moderate or
high-grade disease activity. A positive development was
also seen in the clinical DAI between baseline and LOCF
(Figure 4). The same development was seen in the sig-
moidum, but due to the limited spread of proctitis it was
less distinct (data not shown). Defaecation frequency,
occurrence of rectal bleeding, and general disease activity
improved in all treatment groups (data not shown).
Backing up the main result, efficacy of the study medi-
cation was assessed as "good" or "very good" in 52.2% (12/
23), 47.8% (11/23) 40.9% (9/22), and 40.0% (8/20) of cases
for EcN 40 ml, 20 ml, 10 ml, and placebo, respectively by
the investigators. Similar results were obtained by
patients' assessments (data not shown).
In addition to these clinical parameters, practicability
of treatment was assessed by the patients. Practicability
of Enema application was rated "good" or "very good" by
13/23 (56.5%), 11/23 (47.8%), 12/22 (54.5%), and 9/20
(45.0%) patients in the EcN 40 ml, 20 ml, 10 ml, and pla-
cebo groups, respectively. Ratings on the VAS scale and
self-assessments by patients corresponded well with
those of investigators and clinical findings, but there was
no apparent difference between the treatment groups
(data not shown). The same is true for the global assess-
ment of health. According to both patients and investiga-
tors, the global state of health improved in all treatment
g r o u p s  f r o m  a d m i s s i o n  t o  L O C F  w i t h  n o  d i f f e r e n c e
between EcN and placebo-treated patients.
Safety
The majority of patients indicated "good" to "very good"
tolerance of study medication at LOCF (19/23 [82.6%],
18/23 [78.3%], 17/22 [77.3%] and 18/20 [90.0%] patients)
and in the patient diary (17/23 [73.9%], 17/23 [73.9%], 16/
22 [72.7%], and 17/20 [85.0%] patients in the EcN 40 ml,
20 ml, 10 ml, and placebo group, respectively). In addi-
tion, vital and laboratory parameters did not show any
clinically relevant changes from admission to LOCF. No
difference between the treatment groups was established
(data not shown).
Adverse events
A total of 47/88 patients (53.4%) experienced at least one
adverse event (AE) during the course of the study, with a
similar distribution between the groups (10/23 [43.5%],
15/23 [65.2%], 12/22 [54.5%], and 10/20 [50.0%] for EcN
40 ml, 20 ml, 10 ml, and placebo, respectively). The most
frequently observed AEs comprised gastrointestinal and
thoracic disorders. Twelve of 88 (13.6%) patients experi-
Table 1: Demographics and concomitant medication
Overall 40 ml EcN 20 ml EcN 10 ml EcN Placebo
Age (years) 41.8 ± 12.7 40.5 ± 14.3 42.3 ± 12.0 37.5 ± 9.0 47.4 ± 13.8
Gender (m : f) 49 : 39 13 : 10 13 : 10 11 : 11 12 : 8
Smoking 3/88 2/23 1/23 0/22 0/20
Previous colonic 
surgery
- - 2/23 - 1/20
Antidiarrhoeal, 
antiinflammator
y and/or 
antiinfective 
medication
53/88
60.2%
15/23
65.2%
11/23
47.8%
15/22
68.2%
12/20
60.0%
Systemic 
corticosteroids
14/88
15.9%
3/23
13.0%
3/23
13.0%
6/22
27.3%
2/20
10.0%Matthes et al. BMC Complementary and Alternative Medicine 2010, 10:13
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enced a new concomitant disease. Of these AEs, only one
(aggravated proctosigmoiditis) in the EcN 20 ml group
was regarded as serious. The majority of AEs were "not
related" to the study drug. Only in 2/23 (8.7%), 2/23
(8.7%), 1/22 (4.5%), and 1/20 (5.0%) patients in the EcN
40 ml, 20 ml, 10 ml, and placebo group, respectively, it
was considered as "possibly" or "probably related". Of
these 6 AEs, most were related to flatulence or other gas-
trointestinal disorders. Due to AEs the study medication
was discontinued in 5/23 (21.7%), 7/23 (30.4%), 4/22
(18.2%), and 3/20 (15.0%) patients in the EcN 40 ml, 20
ml, 10 ml, and placebo group, respectively.
Discussion
Up to now, no standard therapy for UC proctitis/procto-
sigmoiditis has been established. Systemic or topical
modulation of the immune response, e.g. with mesalazine
or sulfasalazine (alone or in combination), is a very com-
mon treatment option [23] and may reduce the associ-
ated risk of colon cancer in UC [24]. However, a variety of
side effects have been reported, especially with long-term
use [25,26]. Therefore, an alternative treatment option is
required.
Figure 2 Time to remission, per-protocol analysis (N = 57) and in-
tention-to-treat analysis (N = 88).
Figure 3 Changes in histological findings in rectum, intention-to-treat analysis (N = 88).
Figure 4 Course of clinical DAI between admission and end of 
treatment (LOCF), per- protocol analysis (N = 57).Matthes et al. BMC Complementary and Alternative Medicine 2010, 10:13
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After several positive studies with EcN capsules in UC
remission maintenance [8,27,28] this is the first trial look-
ing at enemas in active disease. Moreover, it is the first
study investigating the efficacy of rectally applied EcN in
UC. The capsules were enteric-coated in order to survive
the gastric juice and open up not before the terminal
ileum is reached. As EcN acts locally in the colon this
trial, by using enemas, aimed at helping patients with rec-
tal disease even better by bringing the probiotic closer to
the focus of inflammation.
E. coli strain Nissle 1917 is one of the best characterized
strains used as a probiotic drug. Different strain-specific
characteristics have been described, e.g. six iron-acquisi-
tion systems, secretion of two microcins, formation of
biofilms under various conditions, a unique structure of
the lipopolysaccharide, and survival in the gut [18,29,30].
Especially with regard to UC, recent research allows for
deeper insight into its modes of action. Here, the induc-
tion of human beta defensin-2 in enterocytes seems to
play a key role in preventing acute attacks [31] with EcN
flagellin being an important contributing factor [32].
Following a phase-I study that showed good tolerance
in 80 patients (data on file at Ardeypharm), we investi-
gated the efficacy of Mutaflor enemas in a phase-II dose-
finding study with clinical remission as the primary end-
point. A clinical DAI ≤ 2 was chosen after clinical obser-
vations suggested DAI ≤ 2.5 being equivalent to a
"patient-defined remission" [21]. Improvement of endo-
scopic and histological scores were considered secondary
e n d p o i n t s .  T h i s  f o c u s  o n  p u r e l y  c l i n i c a l  a s p e c t s  w a s
recently vindicated by findings from Higgins and col-
leagues [33].
A key objective of the treatment of active disease is the
reduction of clinical symptoms relevant to the patient.
Our data suggest that rectal EcN is probably an effective
treatment option. This is corroborated by ratings of the
investigators and patients. Enemas with 40 ml seem most
effective while still being practical. However, the statisti-
cally significant dose response for clinical remission as
well as the improved time to remission should be verified
by a phase-III study. Especially the high number of
patients excluded from the trial for major protocol viola-
tions (in particular for intake of non-permissible con-
comitant medication) necessitates a careful
interpretation of the results. Our observation was unex-
pected since compliance had been good in the previous
outpatient-based study. Recruitment through commu-
nity-based gastroenterologists might have been one con-
tributing factor, but lack of efficacy, especially in the
placebo group, could have also encouraged the use of
additional medication not allowed by the protocol.
Although continuation of oral remission-maintenance
therapy with aminosalicylates or steroids at constant dose
may be considered a weakness of this trial, it was the only
practicable way to investigate patients with acute UC
proctitis and proctosigmoiditis. Disease exacerbations
due to discontinuation of oral medication would probably
have led to even more drop-outs and raised major ethical
concerns.
Conclusion
A dose-dependent efficacy of rectal EcN compared to
placebo was observed in PP patients with active, mild to
moderate distal UC while this effect was not shown in the
ITT population. EcN may represent an effective and well
tolerated alternative or supplementary treatment option
to topically applied aminosalicylates or glucocorticoids.
However, a confirmatory study in a larger subset of
patients is needed in order to gain further evidence. Ene-
mas with 40 ml EcN seem to be most promising.
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